Does Rallies show 13F holders for ANVS?

Yes. Rallies tracks hedge fund and 13F ownership data for ANVS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ANVS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ANVS. It does not provide personalized investment advice.

ANVS (Annovis Bio, Inc.) Stock Analysis - Hedge Fund Holdings

Annovis Bio, Inc. (ANVS) is a publicly traded Healthcare sector company. As of May 20, 2026, ANVS trades at $1.59 with a market cap of $71.03M and a P/E ratio of -1.41. ANVS moved -5.85% today. Year to date, ANVS is -46.85%; over the trailing twelve months it is -8.49%. Its 52-week range spans $1.11 to $10.54. Analyst consensus is buy with an average price target of $12.50. Rallies surfaces ANVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ANVS stock?

Hedge funds tracked by Rallies that own ANVS include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Annovis Bio, Inc..

ANVS Key Metrics

Key financial metrics for ANVS
Metric	Value
Price	$1.59
Market Cap	$71.03M
P/E Ratio	-1.41
EPS	$-1.40
Dividend Yield	0.00%
52-Week High	$10.54
52-Week Low	$1.11
Volume	727.16K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-28.85M
Gross Margin	0.00%

Top Hedge Funds Holding ANVS

Citadel Advisors holds 215.21K shares of ANVS, changed +109.57% as of Dec 31, 2024.

Latest ANVS News

Annovis Bio Launches Public Offering of Stock and Warrants to Fund Phase 3 Study — May 19, 2026
Annovis Hits 85% AD Trial Enrollment, 40% PD Extension; NDA Filings Set — May 15, 2026
Annovis CEO to Present Multi-Protein Alzheimer’s Model, Phase 3 Buntanetap Data on May 13 — May 7, 2026
Annovis’s Buntanetap Shows Dose-Dependent Cognitive Gains, Biomarker Reductions; Phase 3 80% Enrolled — Apr 28, 2026
Annovis Raises $10 Million to Fund Phase 3 Alzheimer’s Trial Through Q2 2027 — Apr 10, 2026

Recent ANVS Insider Trades

Hoffman Michael B bought 713.80K (~$1.50M) on Apr 2, 2026.
Hoffman Michael B bought 30.00K (~$130.19K) on Dec 8, 2025.
Hoffman Michael B bought 15.00K (~$63.60K) on Dec 8, 2025.

ANVS Analyst Consensus

2 analysts cover ANVS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.50.

Common questions about ANVS

Who owns ANVS stock?: Hedge funds tracked by Rallies that own ANVS include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Annovis Bio, Inc..
Does Rallies show 13F holders for ANVS?: Yes. Rallies tracks hedge fund and 13F ownership data for ANVS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ANVS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ANVS. It does not provide personalized investment advice.